Helix BioPharma Corp. (HBP:CA)

Phase I Results at ASCO Bode Well for Lead Drug’s Prospects

May 15, 2020
Report ID: 11469
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Helix BioPharma Corp.
Helix BioPharma Corp.
Healthcare
Biotechnology
Ticker
HBP:CA
Current Price
$0.245 2.08%
Market Cap
$49.0M
Price Target
Refer to Report
Volume
10.8K
52wk Range
$0.19 - $0.29
Related Research Reports
1/4/2021

Q1 F2021: Business Update
Q1 F2021: Business Update (HBP:CA)
8/5/2020

Q3 F2020 Earnings: More Value to Add in 2020
Q3 F2020 Earnings: More Value to Add in 2020 (HBP:CA)
5/15/2020

Phase I Results at ASCO Bode Well for Lead Drug’s Prospects
Phase I Results at ASCO Bode Well for Lead Drug’s Prospects (HBP:CA)
2/12/2020

Pioneer in Cancer Therapy Targeting Tumor Microenvironment (TME)
Pioneer in Cancer Therapy Targeting Tumor Microenvironment (TME) (HBP:CA)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.